Developing Novel Personalized Cancer Vaccines

We are a Phase 2/3 clinical-stage immuno-oncology company developing novel personalized cancer vaccines and developing inhibitors of myeloid derived suppressor cells, or MDSCs, to modulate their immunosuppressive effects on the tumor microenvironment. The company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies like CAR T in the treatment of cancer.

About Us

Overcoming Two Major Obstacles that Limit the Effectiveness of Cancer Immunotherapies

We are advancing two proprietary technologies to overcome:

Primary or Innate Resistance to checkpoint inhibitors or cellular therapies like CAR T related to tumor intrinsic factors such as low mutational burden or low neoantigen load associated with insufficient tumor immunogenicity
Secondary or acquired resistance to immunotherapies, resulting from extrinsic factors that result in highly immunosuppressive tumor microenvironment, the tissue in which the tumor lives and escapes immune recognition

Learn More

Advancing Two Innovative Platform Technologies

SQUARE_Circle_Nanoparticles,Destroying,Cancer,Cells,,Nanoparticles,Cancer,Therapy,,Cancer,Cell,Surrounded

IMMUNE FX™ (IFX™): Personalized Cancer Vaccines Harnessing the Power of the Innate Immune Response

Our IFx technology is designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria and harness the power of innate immunity by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses.

Learn More

Tumor Microenvironment Modulators

Our tumor microenvironment modulators utilize our delta receptor technology to develop small molecule or bifunctional antibody drug conjugates, or ADCs, to inhibit the immune suppressing effects of myeloid derived suppressor cells (MDSCs) on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to allow checkpoint inhibitors and cellular therapies to keep working.

Learn More